Considering treatment options for a recent type 1 diabetes diagnosis?

Gender Both

Age from 18 up to and including 30

BMI from 17 up to and including 28

Calculate your BMI here

Why is this study important?

The investigational drug is designed to stop the immune system from attacking cells in the body that produce insulin. By stopping or limiting the immune system’s attack, the investigational drug may be able to help insulin production in patients who are in the early stage of type 1 diabetes.

For people with type 1 diabetes, there are no treatments available that can cure or even improve their condition. The main treatment option available is frequent insulin injections. While insulin is often effective in helping to manage the effects of the disease, type 1 diabetics must monitor their blood sugar levels throughout the day. As a result, treatment options are needed that might someday slow or prevent the immune system cause of type 1 diabetes.


Who can take part?

To pre-qualify for this study, you must:

  • be 18 to 30 years of age
  • have been diagnosed with type 1 diabetes in the last 6 months
  • take insulin


What happens if you decide to participate?

Eligible patients will receive a total of 4 injections over 6 weeks. The results of this study will provide more information about the investigational drug and its effect on recently diagnosed type 1 diabetes.

You will also continue to take your daily insulin. Your total study participation will last approximately 24 weeks, which includes screening, treatment, and follow-up visits.


You will receive:

All study-related visits, tests, and drugs will be provided at no cost. In addition, reimbursement of £200-£928 for study-related time and travel will be provided.


How to apply

Please register on this website and answer the questions below. If you are eligible, one of the participating clinics will contact you to schedule an appointment, and will also be happy to answer any questions you may have.


The investigational drug is designed to stop the immune system from attacking cells in the body that produce insulin. By stopping or limiting the immune system’s attack, the investigational drug may be able to help insulin production in patients who are in the early stage of type 1 diabetes.

Pharmaceutical companies conduct such studies to learn more about investigational drugs before they are made available to the public. The results of this study will provide more information about the drug’s safety. By taking part in this study, you will make an important contribution to research on early-stage type 1 diabetes.

Imcyse is a clinical-stage biotech company headquartered in Liège, Belgium, created in 2010 as a spin-off of the Catholic University of Leuven (KULeuven). Imcyse’s mission is to develop novel, disease-specific immune therapies to cure and prevent severe, chronic auto-immune, inflammatory and allergic diseases.

What is a clinical study?

  • A clinical study is a scientific study on how a new or existing medicine, product, procedure or treatment works in people.
  • Through clinical studies, doctors can find new and better ways to prevent, detect, diagnose, control and treat illnesses.
  • All clinical studies are carefully monitored and regulated to ensure participant well-being.
  • Participating in a clinical study is completely voluntary and will not affect the normal standard of care you receive.


What is the study about?

As someone who has been recently diagnosed with type 1 diabetes, you’re likely learning about treatment options that will help manage your disease. Your diabetes has developed because your body’s immune system began attacking certain cells in your pancreas that help make insulin. Currently, there is no cure or treatment that can alter the effects of your type 1 diabetes, which means you need insulin shots to help control your blood sugar. 

One option to consider is this research study of an investigational drug that is being evaluated as a ‘therapeutic vaccine’. This type of product has the potential to positively affect the body’s erroneous immune system response which has caused a medical condition or disease, in your case type 1 diabetes.

In this study, doctors primarily want to evaluate the safety of three different doses of the investigational drug in patients who have recently been diagnosed with type 1 diabetes. They also want to collect first evidence of the efficacy of this new approach. They want to compare these doses with a placebo, which looks like the investigational drug, but contains no active medication.

Eligible patients will receive a total of 4 injections over 6 weeks. The results of this study will provide more information about the investigational drug and its effect on recently diagnosed type 1 diabetes.


What will happen during this study?

Before you can participate in this study, you will be screened for eligibility. If you are eligible, and you agree to participate, you will be randomly assigned (like flipping a coin) to receive injections of either the investigational drug or the placebo. You have a 75% chance of receiving the investigational drug and a 25% chance of receiving the placebo.

You will also continue to take your daily insulin, which is currently the standard therapy. Your participation in the study will last approximately 24 weeks in total, which includes screening, treatment, and a follow-up visit.

During your clinic visits for the study, doctors and the study staff will also conduct various tests and assessments to evaluate your health and progress. Some of these tests and assessments include, but are not limited to:

  • Review of your type 1 diabetes and general medical history
  • Vital signs measurements
  • Physical exams
  • Blood and urine sample collections
  • Injection site exams
  • Reviews of your insulin use
  • Reviews of medication you are taking
  • Reviews of any side effects


If you join the study, you can stop taking part at any time. If you choose to leave the study, doctors and the study staff will ask you to undergo some tests and assessments so they can evaluate your safety.


What are the risks and benefits related to this study?

As with any research study, your type 1 diabetes may or may not improve as a result of your participation in this study. The investigational drug used has not been evaluated in humans before as part of a research study. Therefore, not all side effects are known. 

It is possible you could experience a side effect while in this study. Some of the most common side effects related to injections are redness, inflammation, and swelling at the injection site; very similar to what happens with classical vaccinations. The study staff will provide you with a complete list of known side effects related to this product.

Because research studies can affect the health and safety of participants, you will be closely monitored during this study. Researchers designed a protocol for this study, which explains all of the study procedures in complete detail. An independent review board responsible for participant safety reviewed and approved this protocol and requires that it be followed exactly.

What if I have questions?

The study staff is always available to answer any questions or concerns you may have about the study or the investigational drug.

You will receive an email which you must confirm

  • Male
  • Female

Your height or weight does not lead to a realistic outcome

Your height or weight does not lead to a realistic outcome

  • I hereby consent with the processing of my personal data as stipulated in the: Privacy statement

    April 2018

    Link2Trials respects the privacy of the users of its website. We process personal data only for the purpose for which it was provided and in accordance with the Data Protection Act and the Communications Act.

    About us

    Link2Trials is the controller for the processing of your personal data within the meaning of the Data Protection Act.

    Our contact details are:
    Link2Trials B.V.
    Dutch Chamber of Commerce (KvK): 32122355

    What data do we collect?
    When you register an account, you will be asked to fill in data.

    • We will request your name, address, postcode and town/city to contact you; for example, to make appointments or send you information.
    • In addition, we will need your phone number to contact you and send you a reminder message.
    • To create your account, we will ask for your email address. We also need this information to contact you by email; for example, to send you confirmation and reminder emails. In addition, we send emails to inform you of any new trials.
    • We need your address, postcode and town/city in order to display local trials or studies within a certain radius.
    • Your time zone and locale are processed to display the correct time and language for you.
    • Your IP address is processed to protect your account.

    These personal data are necessary for the intended and actual performance of an agreement. Without this information, we will not be able to enter into an agreement or use you as a trial subject. In addition, we will ask you for your prior consent to process of these data.

    Research purposes: ‘special personal data’
    In addition, certain information is requested for research purposes in order to see whether you are a match with the trial in question and to carry out the study. This information includes personal data with respect to your gender, age, ethnicity, level of education, medication use, fertility, height and weight, alcohol consumption, smoking habits, and other medical data and/or data concerning health.

    A large part of this information is ‘special personal data’ in the sense of the GDPR. Because this information is sensitive, we treat it with care. These data will only be processed with your explicit consent.

    With whom do we share your personal data?
    Your personal data may be provided to third parties who will take on part of the processing for the benefit of Link2Trials. For example, we use an external party to provide dedicated hosting for the personal data. This party is certified to store medical data and is a processor within the meaning of the GDPR.

    After you have enrolled in a specific study or project, your personal data will be shared with research institutions, who may or may not contact you to participate in trials or studies.

    We verify in advance whether these organisations are recognised organisations and thus comply with national laws and regulations. These parties shall have access to the personal data of their studies. In principle, your personal data will only be passed on to research institutions in the country where you live.

    Protecting your personal data
    We have taken appropriate technical measures to protect personal data against loss or other forms of unlawful processing. These measures ensure a level of security appropriate to the data that we process. We ensure that the account uses a secure/encrypted SSL connection. In addition, we use two-factor authentication and encrypt your password.

    Cookies are used to ensure that this website works as well as possible and to tailor the content of advertisements to your preferences.

    A cookie is a small file that is sent by our website and is placed on peripheral devices by your browser. The information stored in the cookie may be returned to our website when you revisit the website.

    Advertising cookies
    In order to make advertisements available, Facebook cookies (Facebook Custom Audience, Facebook Impressions and Facebook Pixel) are placed via this website. These cookies ensure, among other things, that advertisements are displayed which are more relevant to you. More information about Facebook cookies can be found at: [].

    Analytical cookies
    We use analytical cookies to learn know how visitors use this website so we can optimise the use of the website. To this end, cookies from Google Analytics are placed via this website. More information about the policies of Google Analytics can be found at: [].

    Social media
    We want to make it as easy as possible for you to share the content of our website via social media. For this reason, we provide a number of social media buttons. To enable sharing information via these social media channels, the AddThis cookie is placed. More information about the AddThis privacy policy can be found at: [].

    To enable sharing information via Facebook, several Facebook cookies are also placed, including Facebook Connect, Facebook Social Plugin and Facebook Social Graph.

    This website contains links and social media buttons to external websites. By clicking on a link or social media button, you will be taken to a website outside this website. These external websites may use cookies. Please refer to the cookie or privacy statement of the website in question.

    Retention period
    We will not keep your data longer than necessary for the purpose for which it was received.

    In principle, your personal data will be saved until you cancel your account with us. When you cancel your account, the personal data will be deleted within 72 hours at the latest.

    We ask inactive accounts to reactivate their account by email. Personal data in accounts that have been inactive for more than 10 years will be deleted after this period.

    The above periods apply unless there are further legal obligations for us to store the data or keep them available for longer.

    You have the right to inspect your personal data and the right to rectify your personal data. If you want to know which of your personal data we process, you can submit a written Data Subject Access Request (DSAR). Should your data be incorrect, incomplete or irrelevant, you can ask us in writing to alter or supplement your data.

    If you have given us your consent to process certain of your data, you are always entitled to withdraw this consent. The withdrawal of this consent does not prejudice the lawfulness of our processing on the basis of your consent, which took place prior to this withdrawal.

    You also have the right to have your personal data erased, the right to restrict their processing and the right to object to their processing. In addition, you have the right to transfer your data or to make them transferable (the so-called ‘right to data portability’). You can also submit a written request to this end.

    ‘Written’ here includes email. You can email your request to us via We will process your request within four weeks.

    You also have the right to complain about the way in which we handle your data. You can submit any such complaints to the Information Commissioner’s Office.

    We reserve the right to make changes to this privacy statement. The amendments shall enter into force on the date announced for their entry into force.

Thank you! Your application has been received! . You will receive an email which you must confirm. You will get a response within weeks
An error has occurred. Please try again or contact Link2Trials
Other trials that may also interest you
  • No matching trials